DiaSorin S.p.A.

History

Year	Detail
2000	The company was founded.
2007	The company was listed on Italian Stock Exchange.
2016	The company acquired Focus Diagnostic to enter molecular diagnostics sector in the U.S.
2018	The company partnered with Qiagen to test latent tuberculosis.
2020	The company made an agreement with TTP to develop Point-of-Care (POC) molecular solution.
2021	The company acquired Luminex Corp. for $1.8 billion.
2022	The company launched molecular reagents for the monkeypox virus.
	The company collaborated with BARDA to support the clinical validation and FDA 510 authorization of LIAISON NES.

Stay Informed

Join our mailing list for the latest report releases and upcoming event notifications.

Headquartered in Boston, Mass., for over 50 years, BCC Research takes pride in being your trusted custom research and data analysts. Our mission is to provide businesses with reputable data and market research reports, so that they gain new perspectives into their field and better understand their target audience. We enable companies to access reliable information, accurate forecasts, and actionable insights, so that they may become leaders in their industry.

AI: Your Say